Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators.
about
Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switchingRearranged NF-kappa B2 gene in an adult T-cell leukemia cell line.Myc suppression of Nfkb2 accelerates lymphomagenesis.Loss of IkappaB alpha-mediated control over nuclear import and DNA binding enables oncogenic activation of c-RelMultiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.NF-κB and cancer: a paradigm of Yin-Yang.Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.Functions of NF-kappaB1 and NF-kappaB2 in immune cell biologyNF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis.SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction.Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cellsNuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responsesBalance between NF-κB p100 and p52 regulates T cell costimulation dependence.Transcription factors as therapeutic targets in lymphoid malignancies.Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells.Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2.The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms.NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function.Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes.Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein.The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies.IkappaBalpha overexpression delays tumor formation in v-rel transgenic mice.Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders.A c-erbB-2 promoter-specific nuclear matrix protein from human breast tumor tissues mediates NF-kappaB DNA binding activity.
P2860
Q22008770-B30E85F9-2694-4B7A-93AC-98ACA248A272Q24554404-E3B422D9-6FBE-4C4D-A406-782EACAEB8CAQ33326327-2DFA4835-9523-404C-A927-4D4BF01F03AFQ33624136-66CF2FF3-917A-45DE-A59B-963F1277A03BQ33778864-555F0E53-D3DB-457D-AC5A-22F23B17BDD0Q33797168-D8A0565A-B761-4B3F-9CB3-0F73CE9AD6C2Q34720640-B5E23AE2-7AEB-4644-B390-49E9E3587EBFQ35232248-AFE29EC2-6AAE-455F-BF71-7C5680541BE6Q35741937-F80D5783-74C5-4126-9FB9-C6C9B524014DQ35815962-1D0B3CB7-399A-4BCA-A229-AEE7E88E2B9BQ35900991-584E1A39-7647-448A-8B85-9389BD5A6367Q36033829-CB0ABB72-58E3-4831-BF88-CDA33D9BB248Q36369816-6573A24B-A94F-4C01-BDC4-C66BB6A651AFQ36400158-B8673F1A-07B8-4D85-AB61-69664B9853ADQ36514124-07DF5FDC-60BA-44A6-A058-A8137DE22852Q37008654-2E08429A-1DCD-4AB9-BEB3-B6CD2D5527C2Q37146086-D7D85C2B-0FB3-42FE-AA0A-57DADE7BABF9Q37477121-BA6B11D6-1FC2-4A2F-9F5E-A4B4040FAFD8Q38324140-01157473-D988-4978-9A67-A26661C0CB7CQ38342766-232D8581-C590-4910-8E12-C88BABF81423Q38355384-52CAD596-6437-4EDA-B2E8-3E71ED008724Q38774316-1A53E487-657E-4B81-A2DF-23EED0500267Q39874406-C152AAA1-DD37-4E6C-AC1D-87C5BA2EFFB9Q40695856-925AFEEE-3835-4D2A-9209-702BBBAE53A7Q40894302-8C56DAAA-0A04-4DA0-8280-03E2AB8859F6Q40896731-18242329-34F8-4BFC-974D-0A8A49124A35Q41043956-58ABF844-6E90-4182-BD5E-4747AD08F7B0Q41342055-A84AF2BE-75BA-4645-945B-2CCD5B3471F8Q41855462-1B456995-C032-45F6-9995-1B1324CF4E97Q42803133-FC503512-9BB3-42B8-B517-E687215E19C8Q54050091-7D9C876D-4FDD-4B5B-B066-D7F0ED92AB20Q54563907-04CD18D0-51AA-4D12-9307-4DEFC5DCB024
P2860
Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@ast
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@en
type
label
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@ast
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@en
prefLabel
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@ast
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@en
P2093
P2860
P356
P1476
Rearranged NFKB-2 genes in lym ...... ctive nuclear transactivators.
@en
P2093
P2860
P304
P356
10.1128/MCB.15.9.5180
P407
P577
1995-09-01T00:00:00Z